Reverse Mergers: From Last Resort to Strategic Choice

The IPO market is open. Reverse mergers are accelerating anyway.

Reverse mergers are no longer simply an alternative to IPOs. They have become a mainstream capital formation pathway for well-capitalized, venture-backed biotechnology companies.

Market Reality: Nearly as Common as IPOs

- 17 reverse mergers announced through mid-August 2026 (already >5× all of 2025)[1]
- 21 biotech IPOs completed through mid-August 2026, raising $6.5B[2]
- ~80% of reverse mergers over the last 3 years included a PIPE or private financing[1]

No longer a story about companies that can't IPO – it's about companies choosing another route.

Hidden Driver: The Downturn Created a Market for Public Infrastructure

The biotech correction did not eliminate public companies. It stranded public company infrastructure, including:

- Public exchange listing
- Cash and financial assets
- SEC reporting infrastructure
- Corporate governance
- Tax assets and legacy value

Public company infrastructure has become a strategic asset that can be reallocated to stronger science.

Recent Reverse Merger Financings[1]



7 recent deals · >$2.0B raised · median ~$320M · legacy holders retain 2–5%

These deals separate responsibilities:

Private company: Science & management
Institutional investors: Capital & validation
Public company: Infrastructure & listing

Why Companies Are Choosing Reverse Mergers

Institutional Validation
- Specialist investors commit before closing
- Capital supports clinical milestones
- Enter public markets fully capitalized

Certainty
- Financing committed before listing
- Valuation negotiated upfront
- Reduced exposure to IPO timing

Speed
- Existing public infrastructure
- Integrated merger & financing
- Faster access to public markets

The competitive advantage is no longer getting public.
It is arriving public with the right capital structure.

Reverse Mergers: From Last Resort to Strategic Choice

The IPO market is open. Reverse mergers are accelerating anyway.

From Alternative Financing to Mainstream Capital Formation

Creates Value When

- **Validated science:** Evidence attracts institutional capital
- **Financing reaches milestones:** Funds value-inflecting events
- **Infrastructure improves execution:** Adds financing flexibility
- **Ownership reflects contribution:** Economics match value

Destroys Value When

- **Public status ≠ validation:** Listing can't fix weak science
- **Poor shell quality:** Liabilities, governance, overhang
- **Incomplete capital formation:** Thin runway moves the problem
- **Not public-ready:** Governance must stand apart

Reverse Merger Decision Lens

Successful deals align three variables:

- **Asset:** Evidence, Differentiation, Catalyst
- **Capital:** Syndicate, PIPE structure, Runway
- **Platform:** Cash, Governance, Legacy liabilities

Value is created only when all three align.

Legacy Model	Emerging Model
IPO first	Institutional capital first
Raise capital after listing	Financing secured at the merger
Listing creates opportunity	Funds clinical milestones
Shell provides a ticker	Platform provides infrastructure
Public status is the goal	Clinical execution is the goal

Market Perspective: Reverse merger + PIPE transactions represented ~28% of all capital raised through U.S. biotechnology going-public transactions in 2026.

Conclusion

For a growing set of well-capitalized, venture-backed biotechs, the reverse merger has become a capital formation strategy of choice and a primary route to the public markets, not a last resort.

It is gaining momentum despite an improving IPO market because it offers financing certainty, institutional validation, and immediate access to public company infrastructure. The modern reverse merger is defined by the science and the syndicate, not the shell.

Reverse mergers are no longer a niche alternative. They have become a mainstream pathway for building public biotechnology companies.

[1] JB Strategy Partners, Biotech Reverse Merger Precedent Deal Activity Tracker; [2] BioBucks, Biotech IPO Tracker 2026; [3] BioBucks, Biotech Venture Funding Tracker 2026. Additional sources: Gibson Dunn, Life Sciences 2026 Outlook; company announcements, SEC disclosures, and Blacklght analysis.

BLACKLIGHT PARTNERS

Illuminating the Undetected

From corporate strategy to commercial diligence, we help life science innovators and investors see the opportunities other miss.

Corporate Strategy

Support investors in validating and executing investment theses across the full investment lifecycle

- Investment Strategy
- Opportunity Identification

Commercial Due Diligence

Develop data-driven commercial and scientific assessments to identify value-creation opportunities

- Buy-side Due Diligence
- Sell-side Forecast Evaluation

Deal Support & Execution

Enable confident deal execution through partner outreach, deal structuring, and negotiation support

- Partner outreach
- Negotiation Support

Blacklight Leadership Has 30+ Years of Strategy and Dealmaking Experience

Ryan L. Coe, Ph.D.
Co-Founder & Partner
University of Virginia | University of Washington

Leslie Gautam, M.B.A.
Co-Founder & Partner
UCLA | Columbia Business School

Illuminating the Undetected

Scientific Foundation (MIT)

Deep Understanding of Innovator Technology

Strategic Advice (Triangle Insights Group)

200+ projects for 50+ clients

Deep Buy/Sell Side Transaction Experience (UBS, Houlihan Lokey, Torreya)

>25 deals and >$15B in transaction value

Operating Perspective (Maipl Therapeutics, Purdue, Noven, EnteraBio, Zipcode Bio)

Chief Strategy / Business Officer for 3 Companies

La Jolla, CA | New York, NY | Chicago, IL

www.blacklightpartners.com

BLACKLIGHT PARTNERS